

## 書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書籍名	出版社名	出版地	出版年	ページ
高橋 祥友	高齢期の痴呆と精神疾患、自殺	一番ヶ瀬康子	高齢者心理学	建帛社	東京	2004	41-52
高橋 祥友	自殺未遂；「死にたい」と「生きたい」の心理学.	高橋 祥友	自殺未遂；「死にたい」と「生きたい」の心理学.	講談社	東京	2004	
高橋 祥友	自殺の問題.	精神医学講座 担当者会議・編	「専門医をめざす人の精神医学」	医学書院	東京	2004	524-529
高橋 祥友	自殺のポストベンション；遺された人々への心のケア.	高橋祥友、福岡詳・編	自殺のポストベンション；遺された人々への心のケア.	医学書院	東京	2004	
高橋 祥友	希死念慮・自殺企図	武田雅俊、鹿島晴雄・編	「コア・ローテーション精神科」	金芳堂	東京	2004	228-234
高橋 祥友	自殺観念・自殺企図	水島裕、黒川清・編	「今日の治療と看護」（改訂第2版）	南江堂	東京	2004	187-189
高橋 祥友	自殺	精神医学講座 担当者会議・監修	「気分障害治療ガイドライン」	医学書院	東京	2004	164-172
高橋 祥友	働き盛りの自殺を防ぐには：こころの風邪に気をつけて	上島国利、樋口輝彦、野村総一郎・編	「今日のうつ病」	アルタ出版	東京	2004	85-89
高橋 祥友	自殺者数の時代的推移．自殺の兆候、危機介入の実際	石田弓	自己を追いつめる青少年の心	北大路書房	京都	2005	32-34 34-39 98-103
高橋 祥友	自殺の危険を評価する際の落とし穴	上島 国利	うつ病診療のコツと落とし穴	中山書店	東京	2005	36-37
高橋 祥友	高齢者の自殺	武田雅俊・編	現代 老年精神医療	永井書店	東京	2005	546-551

高橋 祥友	自殺	野村 総一郎 高橋 祥友 川上 憲人	健康管理室で役立つところの医学	南江堂	東京	2005	121-126
本橋 豊 高橋 祥友 中山 健夫 川上 憲人 金子 義博	STOP! 自殺：世界と日本の取り組み	本橋 豊 高橋 祥友 中山 健夫 川上 憲人 金子 義博	STOP! 自殺：世界と日本の取り組み	海鳴社	東京	2006	
高橋 祥友	新訂増補版・自殺の危険：臨床的評価と危機介入	高橋 祥友	新訂増補版・自殺の危険：臨床的評価と危機介入	金剛出版	東京	2006	
高橋 祥友	自殺予防	高橋 祥友	自殺予防	岩波書店	東京	2006	
高橋 祥友	医療者が知っておきたい自殺のリスクマネジメント第2版	高橋 祥友	医療者が知っておきたい自殺のリスクマネジメント第2版	医学書院	東京	2006	
高橋 祥友	うつ病における自殺の発生率	上島 国利 三村 将 中込 和幸 平島 奈津子	EBM精神疾患の治療自殺既遂後の対応	中外医学社	東京	2006	119-112
高橋 祥友	あなたの「死にたい、でも生きたい」を助けてたい	高橋 祥友	あなたの「死にたい、でも生きたい」を助けてたい	講談社	東京	2007	
高橋 祥友	自殺予防	防衛医学編集委員会編	防衛医学			2007	602-613

### Ⅲ. 研究成果の刊行物・別刷

## 自殺予防対策のための自殺死亡統計

藤田 利治

### Key Words

suicide death, vital statistics, spatial clustering, unemployment, divorce

### 1 はじめに

1998年に前年と比べて35%増と急増した自殺死亡はその後も減少に転ずることなく、2003年には34,427人(警察庁)と死亡統計始まって以来の最悪な状態を更新している。自殺死亡急増に対する的確かつ効率的な対策を実施するためには、自殺死亡の実態把握を正確に行うことが不可欠である。本稿では、厚生労働省の人口動態調査に基づいて、最近の自殺死亡急増の保健統計上の特徴を整理する。

### 2 近年の自殺死亡急増の特徴

歴史的には1950年以降において2回の自殺死亡急増がすでに観察されている<sup>1,2)</sup>。すなわち、1958年(23,641人)をピークとする1955年前後の第1の急増、1986年(25,667人)をピークとする1985年前後の第2の急増であり、1998年以降の急増は第3のものといえる(図1)。第2の急増と1998年以降の急増の多くの部分は男性によることが明らかであり、1998年では男性は70%(22,349人)を占めていた。また、男性の自殺死亡率と完全失業率(総務省労働力調査)の年次推

移の間には極めて強い相関が観察されている。自殺予防において社会的、経済的な観点からの対策の必要性を示唆していると考えられる。この点については、後にさらに検討する。一方、女性では自殺死亡と失業との年次推移にはほとんど関連はみられていない。

2000年に策定された「21世紀における国民健康づくり運動(健康日本21)」においては、2010年までに自殺死亡数を2万2千人に減らすことが目標の1つに掲げられている。自殺死亡の第2の急増がみられた1983年以降において、目標の2万2千人未満であったのは1989~1995年までの7年間であった。そこで、1989~1995年までの7年間と比較し、3万人を超える自殺死亡数が観察されている1998~2000年までの3年間の自殺死亡急増について、その特徴を整理する。あわせて、1983~1987年までの第2の急増期との違いについても触れる。

女性では、1989~1995年から1998~2000年にかけての15歳以上の自殺死亡率は人口10万人当たり13.9から16.3へと17%増であった。1983~1987年の15歳以上の自殺死亡率は17.0であったことから、1998~2000年での増加は第2の急増期をわずかに下回るものといえる。年齢階級別には、1989~1995年と比べて、1998~2000年の方が70歳未満の各5歳階級でやや高率であったが、70歳以上ではむしろ低率であった(図2)。また、第2の急増期である1983~1987年においては、




図1 自殺死亡率と完全失業率の年次推移

1989～1995年と比べてすべての年齢階級で自殺死亡率が高く、特に高年齢で高率であった。

一方、男性では、1989～1995年から1998～2000年にかけての15歳以上の自殺死亡率は、人口10万人当たり26.1から41.8へと60%上昇し、

女性と比べて極めて大きな増加がみられた。特に、50～64歳までの各5歳階級での自殺死亡率の上昇(差)は、人口10万人当たり20をはるかに超える激しいものであった(図2)。自殺死亡率の比(1998～2000年/1989～1995年)では、15～69




図2 年齢階級別自殺死亡率の期間による相違

歳までの各5歳階級のほとんどで50%を超える激増がみられた。1989～1995年から1998～2000年にかけて1年間の自殺死亡数の平均は20,556人から30,849人へと増加したが、その4分の3以上は15～69歳までの男性における増加によるもので

あった。特に、45～69歳までの中高年男性の増加は全増加の62%に相当していた。また、1983～1987年での15歳以上の自殺死亡率は34.2であり、1989～1995年と比べて、年齢階級別には55歳未満と65歳以上で自殺死亡率が明らかに高く

表1 15歳以上の自殺死亡率の増加の高位10都道府県

1989～1995年との比較

	1983～1987年での増加					1998～2000年での増加					
	自殺死亡数 (/年)		自殺死亡率 (/100,000)		比	自殺死亡数 (/年)		自殺死亡率 (/100,000)		比	
	1989～ 1995年	1983～ 1987年	1989～ 1995年	1983～ 1987年		1989～ 1995年	1998～ 2000年	1989～ 1995年	1998～ 2000年		
男性											
北海道	613	868	27.6	40.6	1.47	大阪府	894	1,658	25.1	46.1	1.84
徳島県	81	115	25.2	36.9	1.47	奈良県	112	208	20.6	36.1	1.76
大分県	135	187	28.7	41.1	1.43	京都府	248	442	23.7	41.4	1.75
岡山県	180	243	23.7	33.9	1.43	神奈川県	713	1,309	20.7	36.0	1.74
愛媛県	176	242	30.5	43.1	1.41	北海道	613	1,085	27.6	47.4	1.72
高知県	112	156	35.6	50.2	1.41	宮城県	216	389	23.9	40.3	1.68
群馬県	219	282	27.5	38.6	1.40	東京都	1,129	1,938	22.4	37.5	1.68
和歌山県	138	187	33.1	46.3	1.40	兵庫県	533	919	25.1	41.7	1.66
山口県	188	257	31.0	43.4	1.40	埼玉県	594	1,066	21.9	36.5	1.66
福島県	222	292	27.0	37.5	1.39	佐賀県	95	162	28.9	47.9	1.66
女性											
愛媛県	96	136	14.4	21.1	1.47	神奈川県	368	529	11.2	15.0	1.34
大分県	72	96	13.3	18.2	1.37	大阪府	468	632	12.5	16.6	1.33
山口県	97	129	14.0	19.2	1.37	沖縄県	52	73	10.6	13.8	1.30
群馬県	145	178	17.4	23.2	1.33	東京都	627	835	12.4	16.0	1.29
滋賀県	69	81	13.3	17.7	1.33	三重県	106	141	13.7	17.5	1.28
熊本県	102	130	12.7	16.8	1.33	山口県	97	124	14.0	17.8	1.27
島根県	63	79	18.5	23.9	1.29	熊本県	102	132	12.7	15.8	1.25
鹿児島県	127	160	16.1	20.8	1.29	兵庫県	310	399	13.4	16.5	1.24
徳島県	53	66	14.5	18.7	1.29	福岡県	265	345	12.6	15.5	1.23
茨城県	167	192	14.1	18.1	1.28	北海道	327	416	13.3	16.3	1.22

なっていた。

自殺死亡数が2万2千人未満であった1989～1995年と比べて、15歳以上の自殺死亡率の比が高い10都道府県を、1983～1987年と1998～2000年について表1に示した。男性については、1998～2000年での急増は大阪府で最も著しく、次いで奈良県、京都府と近畿の府県が続き、神奈川県、東京都、埼玉県といった関東の都県も高位10位までに含まれていた。自殺死亡数の増加は自殺死亡率の上昇よりさらに大きなものであり、1998年以降の急増は人口規模の大きな都道府県で顕著であることが分かる。一方、第2の急増期である1983～1987年においては、近畿および関東の都府県はほとんど高位10位までに含まれていなかった。1998年以降の自殺死亡急増は、第2

の急増期とは地理的特徴を異にしている。

女性についても、1998～2000年での高位10位に神奈川県、大阪府、東京都および兵庫県といった近畿と関東の都府県が含まれ、やはり大都市部で自殺死亡増加が著しい傾向がみられた。一方、第2の急増期である1983～1987年においては、男性と同様、近畿と関東の都府県での大きな増加はみられなかった。

次に、自殺死亡の地理的特徴をさらに詳細にみるために、二次医療圏を単位とする自殺死亡率(ベイズ推定値)を用いて検討する<sup>3-5)</sup>。1998～2000年での15歳以上の男性についての二次医療圏別の自殺死亡率(ベイズ推定値)による地図を、図3に示した。東北地方(秋田県、岩手県、青森県)を含む日本海側および九州地方(宮崎県、鹿

1998～2000年：15歳以上の男性




図3 二次医療圏別の自殺死亡率（ベイズ推定値）

児島県など)は従来から自殺死亡率が高率であることが指摘されてきたが、自殺死亡急増後の1998～2000年においても依然として人口10万人当たりの自殺死亡率が55を超える二次医療圏がこれらの地域に集積していた。図は省略するが、1989～1995年および1983～1987年においても、これらの地域の自殺死亡率が相対的に高率であることが確認されている。1998年以降の急増はこれらの地域でも起きており、依然として自殺予防対策の推進が必要な状況に変わりはない。

一方、1989～1995年対する1998～2000年の15歳以上の男性の自殺死亡率（ベイズ推定値）の比(×100)を用いて二次医療圏ごとの自殺死亡増加の状況を示したのが、図4である。100の場合に両期間の自殺死亡率（ベイズ推定値）は等しく、175は1989～1995年と比べて1998～2000年の自殺死亡率（ベイズ推定値）が1.75倍であることを表している。大都市部の二次医療圏については人口が多いわりには面積が狭いことから視覚的には目立たないとも思われるが、1.75倍を超える自殺




図4 二次医療圏別の自殺死亡率（ベイズ推定値）の変化

死亡率が急増した地域には近畿（大阪府，京都府および兵庫県における11の二次医療圏）と関東（東京都，神奈川県，埼玉県および千葉県における，11の二次医療圏）の人口規模の大きな二次医療圏が多く含まれていた。

1985年前後の第2の急増期については，種々の統計資料を詳細に検討したうえで，経済生活問題，特に「サラ金」問題の関与が強いことが報告されている<sup>6)</sup>。しかし，1989～1995年と比べて1983

～1987年（第2の急増期。図は省略）には大都市部での自殺死亡増加の現象はみられなかった。

女性についても，1989～1995年と比べて1998～2000年での自殺死亡率が1.30倍を超える上昇を示した二次医療圏には，近畿および関東とともに札幌（北海道）などの都市部の人口の多い二次医療圏が含まれていた。

表2 1995年度から2000年度にかけての自殺死亡の増加と職業および配偶関係

	男性				女性									
	自殺死亡率 (/10万人)		死亡率差の成分への分解		自殺死亡率 (/10万人)		死亡率差の成分への分解							
	1995年度	2000年度	自殺死亡率 /10万人	要因カテゴリ別の 死亡率差の寄与 構成変化の寄与	1995年度	2000年度	自殺死亡率 /10万人	要因カテゴリ別の 死亡率差の寄与 構成変化の寄与						
総計	26.7	41.2	14.45	11.25	77.8%	3.20	22.2%	13.0	15.4	2.45	1.78	72.7%	0.67	27.3%
職業														
専門的・技術的職業 従事者	14.3	35.2	20.92	1.89	13.1%	0.02	0.1%	4.3	6.6	2.27	0.15	6.0%	0.02	0.9%
管理的職業従事者	15.8	42.0	26.16	1.01	7.0%	-0.47	-3.3%	23.0	31.8	8.82	0.04	1.5%	-0.03	-1.3%
事務従事者	15.8	19.7	3.82	0.33	2.3%	-0.04	-0.3%	3.2	3.6	0.41	0.06	2.3%	-0.02	-0.6%
販売従事者	13.3	20.2	6.86	0.80	5.5%	-0.02	-0.1%	4.8	6.2	1.40	0.09	3.6%	-0.02	-0.8%
サービス職業従事者	31.6	50.3	18.66	0.68	4.7%	0.07	0.5%	6.7	8.4	1.73	0.11	4.4%	0.04	1.7%
保安職業従事者	14.3	24.3	10.04	0.18	1.2%	0.01	0.1%	28.4	21.6	-6.78	-0.01	-0.2%	0.00	0.1%
農林漁業作業者	41.4	54.1	12.73	0.49	3.4%	-0.38	-2.6%	15.7	17.6	1.81	0.05	2.0%	-0.10	-4.2%
運輸・通信従事者	21.8	35.0	13.22	0.56	3.9%	-0.09	-0.6%	20.0	27.8	7.79	0.02	0.7%	-0.01	-0.4%
技能工・生産工程作 業及び労務作業	13.9	16.0	2.09	0.54	3.7%	-0.27	-1.9%	3.1	3.4	0.27	0.03	1.1%	-0.02	-1.0%
分類不能の職業	548.0	554.0	5.97	0.04	0.2%	2.01	13.9%	250.0	205.9	-44.07	-0.20	-8.1%	0.59	24.0%
無職 (完全失業者を含む)	46.9	64.5	17.59	4.74	32.8%	2.37	16.4%	18.5	21.2	2.74	1.46	59.4%	0.22	8.9%
配偶関係														
有配偶	21.9	34.4	12.49	7.76	53.7%	-0.21	-1.5%	10.0	11.7	1.74	1.02	41.5%	-0.10	-4.1%
未婚	24.8	35.8	10.93	3.49	24.2%	-0.09	-0.6%	10.0	13.0	3.04	0.72	29.5%	-0.04	-1.6%
死別	80.9	103.5	22.68	0.59	4.1%	0.14	1.0%	28.3	30.3	1.95	0.25	10.2%	0.07	2.9%
離別	133.3	209.9	76.60	1.88	13.0%	0.86	5.9%	28.1	35.8	7.67	0.31	12.5%	0.22	9.0%
不詳	11.9	11.1	-0.79	-0.01	0.0%	0.05	0.3%	6.5	3.8	-2.75	-0.02	-0.7%	0.02	0.7%

### 3 自殺死亡急増と失業および離婚

国勢調査の実施年度においては、職業や配偶関係といった情報が人口動態調査死亡票について追加収集されていることから、個人レベルの要因についてのやや詳細な検討が可能である。ここでは、1995年度と2000年度の15歳以上の自殺死亡率の差を、職業および配偶関係との関係から分析する。

2つの年度の自殺死亡率の差は、次のように2つの成分に分解することができる。すなわち、1995年度と2000年度の自殺死亡率をそれぞれ $R_1$ と $R_2$ 、その差を $\Delta R$ とおくと、

$$\begin{aligned}\Delta R &= R_2 - R_1 = \sum_i w_{i2} R_{i2} - \sum_i w_{i1} R_{i1} \\ &= \sum_i \frac{w_{i1} + w_{i2}}{2} \times (R_{i2} - R_{i1}) + \sum_i (w_{i2} - w_{i1}) \times \frac{R_{i1} + R_{i2}}{2}\end{aligned}$$

ただし、 $i$ は職業カテゴリなどを示す添字

$w_{i1}$ と $w_{i2}$ は1995年度と2000年度の職業ないし配偶関係の各要因カテゴリ $i$ の人口割合の重み

$R_{i1}$ と $R_{i2}$ は1995年度と2000年度の職業ないし配偶関係の各要因カテゴリ $i$ での自殺死亡率

となる。右辺の第1項は「各要因カテゴリの自殺死亡率の変化による成分」(以下、カテゴリごとの死亡率増加)、第2項は「各要因カテゴリの構成の変化による成分」(以下、カテゴリの人口割合変化)に相当する。

1995年度と2000年度の15歳以上の自殺死亡率(人口10万人当たり)は、男性では26.7から41.2へと著しく増加し、女性では13.0から15.4への増加がみられた(表2)。男性の自殺死亡率差(人口10万人当たり)に関しては、職業において各カテゴリでの死亡率増加の寄与とともに、人口割合変化の寄与がかなりの大きさを示した。無職には、通学・高齢などのため仕事を持たない非労働力人口とともに完全失業者が含まれているが、無職は18.7%(1995年度)から29.1%(2000年度)へ人口割合変化し、全体の自殺死亡率差への寄与は16.4%に相当した。また、無職での死亡率増加の寄与も32.8%と大きなものであり、両者をあわせて自殺死亡率差の実に約50%が無職にかかわ

るものであった。失業・高齢などのための無職の増加が、近年の自殺死亡率増加に極めて大きく影響していることを端的に示す数字と考えられる。配偶関係については、離別の人口割合変化による寄与は5.9%であり、死亡率増加による寄与は13.0%であった。15歳以上に占める離別者の割合は2.7%にすぎないのに対して、自殺死亡率差の18.9%は離別に関係しているということであり、相対的に大きな問題であるといえる。

女性での自殺死亡率差に関して、職業において寄与が大きかったのはやはり無職であり、53.8%の人口割合に対して自殺死亡率差の68.2%が無職におけるものであった。配偶関係では、有配偶の人口割合は58.2%であるのに対して、死亡率差への寄与は37.5%にすぎなかった。一方、離別の人口割合は4.4%であるが、死亡率差の21.5%を占めており、女性においても離別は自殺死亡にかかわる大きな問題といえる。

### 4 おわりに

自殺死亡数(年平均)は、1989～1995年の20,556人から1998～2000年の30,849人へと1万人を超える急増がみられているが、その4分の3以上に相当する増加が15～69歳までの男性において発生していた。特に45～69歳までの男性での自殺死亡数の増加は、全増加の62%に相当する大きさであった。男性での自殺死亡率の上昇は、従来から高率であった東北地域を含む日本海側および九州地域でも起きていた。しかし、これまでやや自殺死亡率が低い傾向にあった近畿および関東などの大都市部での増加が大きな関与を果たしていた。また、男性と比較して女性の自殺死亡数の増加はわずかではあるが、女性の近年の自殺死亡数の増加が近畿および関東などの大都市部において明らかであったことも留意すべき点である。また、こうした自殺死亡急増は、失業や離婚の急増などの社会的、経済的な問題が強く関連していることが明らかになった。こうした統計を踏まえて、自殺予防対策を推進する必要がある。

## 文献

- 1) 厚生省大臣官房統計情報部：人口動態統計特殊報告．自殺死亡統計，1999
- 2) 谷口たみ子，石川正文，飯野一浩ほか：人口動態統計に見る自殺の現状．厚生 の 指標 45：3-9，1998
- 3) 丹後俊郎：死亡指標の経験的ベイズ推定量について；疾病地図への適用．応用統計学 17：81-96，1988
- 4) 平子哲夫，佐伯則英，中田 正：人口動態市区町村別統計へのベイズ統計の応用について；(1) 標準化死亡比への応用．厚生 の 指標 46：3-11，1999
- 5) 藤田利治，谷畑健生，三浦宜彦：1998年以降の自殺死亡急増の地理的特徴．厚生 の 指標 50：27-34，2003
- 6) 福富和夫，西田茂樹，林 謙治ほか：自殺の急増について．厚生 の 指標 33：3-9，1986

## ☐学会告知板

## 精神分析的精神医学会第3回大会

会 期：平成17年3月3～5日

会 場：東京大学医学系研究科教育研究棟（東京都文京区本郷7-3-1）

13階 第3・第4セミナー室 14階 鉄門記念講堂

テーマ：「精神医学における精神分析」

会 長：衣笠 隆幸（広島市精神保健福祉センター）

実行委員長：菊地 孝則（井之頭病院）

プログラム：

3月3日（木）

プレコングレス（症例検討会）

症例提示者：小林 要二（関東中央病院神経精神科）

助言者：衣笠 隆幸

3月4日（金）

シンポジウム「摂食障害の臨床」

シンポジスト：衣笠 隆幸，菊地 孝則，舘 哲朗（東海大学健康科学部）

皆川 邦直（法政大学・サイコセラピーインターナショナル）

指定討論者：狩野力八郎（東京国際大学）

司会：福井 敏（精神分析研究室），白波瀬丈一郎（慶応義塾大学精神神経科学教室）

特別記念講演「精神医学と精神分析」土居 健郎

教育講演「コミュニティーセラピー」相田 信男（群馬病院）

「日本語臨床」北山 修（九州大学）

研究発表

3月5日（土）

教育講演

「間主観性の理論と臨床」丸田 俊彦（埼玉県立医療センター・埼玉県立精神保健福祉センター）

「精神分析の精神科診察への応用」高橋 哲郎（精神分析セミナー）

症例検討会

症例提示者：木村 一優（陽和病院）

助言者：小野 泉（舟入病院小児心療科）

研究発表

対 象：医師

参加費：プレコングレス／3,000円，本大会／会員12,000円・非会員1,300円

参加ご希望の方は事前にお申し込みください。当日直接参加も可能ですが，その場合，医師の身分を証明するものを御提示ください。

＜プログラムの内容に関しては，やむを得ない事情で一部変更になることがございますので，予めご了承ください。＞

問い合わせ先：

大会事務局：井之頭病院 FAX 0422-44-0388 E-mail: AAPP3@jcom.home.ne.jp

# Suicide Prevention Strategies

## A Systematic Review

J. John Mann, MD

Alan Apter, MD

Jose Bertolote, MD

Annette Beautrais, PhD

Dianne Currier, PhD

Ann Haas, PhD

Ulrich Hegerl, MD

Jouko Lonnqvist, MD

Kevin Malone, MD

Andrej Marusic, MD, PhD

Lars Mehlum, MD

George Patton, MD

Michael Phillips, MD

Wolfgang Rutz, MD

Zoltan Rihmer, MD, PhD, DSc

Armin Schmidtke, MD, PhD

David Shaffer, MD

Morton Silverman, MD

Yoshitomo Takahashi, MD

Airi Varnik, MD

Danuta Wasserman, MD

Paul Yip, PhD

Herbert Hendin, MD

**S**UICIDE IS A SIGNIFICANT PUBLIC health issue. In 2002, an estimated 877 000 lives were lost worldwide through suicide, representing 1.5% of the global burden of disease or more than 20 million disability-adjusted life-years (years of healthy life lost through premature death or disability).<sup>1</sup> The highest annual rates are in Eastern Europe, where 10 countries report more than 27 sui-

**CME available online at**  
[www.jama.com](http://www.jama.com)

**Context** In 2002, an estimated 877 000 lives were lost worldwide through suicide. Some developed nations have implemented national suicide prevention plans. Although these plans generally propose multiple interventions, their effectiveness is rarely evaluated.

**Objectives** To examine evidence for the effectiveness of specific suicide-preventive interventions and to make recommendations for future prevention programs and research.

**Data Sources and Study Selection** Relevant publications were identified via electronic searches of MEDLINE, the Cochrane Library, and PsychINFO databases using multiple search terms related to suicide prevention. Studies, published between 1966 and June 2005, included those that evaluated preventative interventions in major domains; education and awareness for the general public and for professionals; screening tools for at-risk individuals; treatment of psychiatric disorders; restricting access to lethal means; and responsible media reporting of suicide.

**Data Extraction** Data were extracted on primary outcomes of interest: suicidal behavior (completion, attempt, ideation), intermediary or secondary outcomes (treatment seeking, identification of at-risk individuals, antidepressant prescription/use rates, referrals), or both. Experts from 15 countries reviewed all studies. Included articles were those that reported on completed and attempted suicide and suicidal ideation; or, where applicable, intermediate outcomes, including help-seeking behavior, identification of at-risk individuals, entry into treatment, and antidepressant prescription rates. We included 3 major types of studies for which the research question was clearly defined: systematic reviews and meta-analyses (n=10); quantitative studies, either randomized controlled trials (n=18) or cohort studies (n=24); and ecological, or population-based studies (n=41). Heterogeneity of study populations and methodology did not permit formal meta-analysis; thus, a narrative synthesis is presented.

**Data Synthesis** Education of physicians and restricting access to lethal means were found to prevent suicide. Other methods including public education, screening programs, and media education need more testing.

**Conclusions** Physician education in depression recognition and treatment and restricting access to lethal methods reduce suicide rates. Other interventions need more evidence of efficacy. Ascertaining which components of suicide prevention programs are effective in reducing rates of suicide and suicide attempt is essential in order to optimize use of limited resources.

*JAMA. 2005;294:2064-2074*

[www.jama.com](http://www.jama.com)

cides per 100 000 persons. Latin American and Muslim countries report the lowest rates, fewer than 6.5 per 100 000.<sup>2</sup> In the United States, in 2002, suicide accounted for 31 655 deaths, a rate of 11.0 per 100 000 per year,<sup>3</sup> and general population surveys document a suicide attempt rate of 0.6% and a suicide ideation rate of 3.3%,<sup>4</sup> represent-

ing a huge human tragedy and an estimated \$11.8 billion in lost income.<sup>5</sup>

Suicidal behavior has multiple causes that are broadly divided into proximal

**Author Affiliations** are listed at the end of this article. **Corresponding Author:** J. John Mann, MD, Department of Neuroscience, New York State Psychiatric Institute, 1051 Riverside Dr, Box 42, New York, NY 10032 (jjm@columbia.edu).

stressors or triggers and predisposition.<sup>6</sup> Psychiatric illness is a major contributing factor, and more than 90% of suicides have a *Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV)* psychiatric illness,<sup>7-13</sup> with some exceptions, such as in China.<sup>14</sup> Mood disorders, principally major depressive disorder and bipolar disorder, are associated with about 60% of suicides.<sup>7,8,10,15,16</sup> Other contributory factors include availability of lethal means, alcohol and drug abuse, access to psychiatric treatment, attitudes to suicide, help-seeking behavior, physical illness, marital status, age, and sex.<sup>6</sup> To address these causes, suicide prevention involves a multifaceted approach with particular attention to mental health. The FIGURE illustrates the multiple factors involved in suicidal behavior<sup>6</sup> and indicates where specific preventive interventions are being directed. Suicide prevention is possible because up to 83% of suicides have had contact with

a primary care physician within a year of their death and up to 66% within a month.<sup>17,18</sup> Thus, a key prevention strategy is improved screening of depressed patients by primary care physicians and better treatment of major depression. This review considers what is known about this and other prevention strategies to permit integration into a comprehensive prevention strategy.

Suicide experts from 15 countries met in Salzburg, Austria, in August 2004 to review efficacy of suicide prevention interventions. The 5-day workshop identified 5 major areas of prevention: education and awareness programs for the general public and professionals; screening methods for high-risk persons; treatment of psychiatric disorders; restricting access to lethal means; and media reporting of suicide.

**DATA SOURCES**

An electronic literature search of all articles published between 1966 and June 2005 was conducted via MEDLINE, the


Cochrane Library, and PsychINFO to identify reports evaluating suicide prevention interventions. An initial search used the MEDLINE identifier *suicide* (including the subheading *suicide, attempted*) and the subheading *prevention and control*, following that *suicide* was combined with the following identifiers: *depression, health education, health promotion, public opinion, mass screening, family physicians, medical education, primary health care, antidepressive agents, psychotherapy, schools, adolescents, methods, firearms, overdose, poisoning, gas poisoning, and mass media*. We identified 5020 articles, which were not bound by the 5 major areas identified during the workshop. Abstracts were reviewed and full-text articles that met inclusion criteria were retrieved. All reports were reviewed by at least 2 authors.

**Study Selection**

Studies were included if they reported on either the primary outcomes of interest, namely completed and attempted suicide and suicidal ideation; or, where applicable, intermediate outcomes, including help-seeking behavior, identification of at-risk individuals, entry into treatment, and antidepressant prescription rates.

We included 3 major types of studies for which the research question was clearly defined as assessment of efficacy or effectiveness of prevention programs in terms of the above primary or secondary outcomes; (1) systematic reviews and meta-analyses (n=10) for which the search strategy was comprehensive and the methodological quality of primary studies was critically appraised; (2) quantitative studies, either randomized controlled trials (n=18), or cohort studies (n=24); and (3) ecological or population based studies (n=41). TABLE 1 and TABLE 2 detail study type, study population, and preventive intervention tested and rate the studies according to the scheme proposed by the Oxford Centre for Evidence Based Medicine.<sup>112</sup> Randomized controlled trials provide the most compelling evidence of efficacy while findings of naturalistic studies are largely correlational, indicating that their outcomes need further testing.

**Figure.** Targets of Suicide Prevention Interventions



Circled letters refer to relevant prevention interventions listed on right.

SUICIDE PREVENTION STRATEGIES

**Table 1.** Study Type, Level of Evidence, Population, and Prevention Strategy

Source	Study Type	Level*	Population	Prevention Strategy
Gunnell et al, <sup>19</sup> 2005	Meta-analysis	1A	RCTs in UK psychiatric patients	Antidepressant use
Fergusson et al, <sup>20</sup> 2005	Meta-analysis	1A	RCTs in psychiatric patients	Antidepressant use
Khan et al, <sup>21</sup> 2003	Meta-analysis	1A	RCTs in US psychiatric patients	Antidepressant use
Ploeg et al, <sup>22</sup> 1996	Systematic review	2A	Adolescents	Curriculum-based programs
Guo and Harstall, <sup>23</sup> 2002	Systematic review	2A	Adolescents	Curriculum-based program
Pignone et al, <sup>24</sup> 2002	Systematic review	2A	Primary care patients	Screening for depression in primary care
Feightner, <sup>25</sup> 1994	Systematic review	2A	Primary care patients	Screening for depression in primary care
Gaynes et al, <sup>26</sup> 2004	Systematic review	2A	Primary care patients	Screening for suicide risk in primary care
Gilbody et al, <sup>27</sup> 2003	Systematic review	2A	Primary care patients	Detecting and treating depression in primary care
Hawton et al, <sup>28</sup> 2000	Systematic review	2A	Patients who attempted suicide	Psychotherapy
Aseltine and DeMartino, <sup>29</sup> 2004	RCT	1B	Adolescents	Curriculum-based program
Thompson et al, <sup>30</sup> 2000	RCT	1B	Primary care patients	Detecting and treating depression in primary care
Bruce et al, <sup>31</sup> 2004	RCT	1B	Older primary care patients	Detecting and treating depression in primary care
Glick et al, <sup>32</sup> 2004	RCT	1B	Adults with schizophrenia spectrum disorders	Clozapine
Meltzer et al, <sup>33</sup> 2003	RCT	1B	Adults with schizophrenia spectrum disorders	Clozapine
Thies-Flechner et al, <sup>34</sup> 1996	RCT	1B	Adults with affective disorders	Lithium
Brown et al, <sup>35</sup> 2005	RCT	1B	Suicide attempters	Psychotherapy
Guthrie et al, <sup>36</sup> 2001	RCT	1B	Suicide attempters	Psychotherapy
Bateman and Fonagy, <sup>37</sup> 2001	RCT	1B	Borderline personality disorder patients	Psychotherapy
Motto and Boström, <sup>38</sup> 2001	RCT	1B	Suicide attempters	Follow-up care: postal contact program
Cedereke et al, <sup>39</sup> 2002	RCT	1B	Suicide attempters	Follow-up care: telephone contact program
Allard et al, <sup>40</sup> 1992	RCT	1B	Suicide attempters	Follow-up care
Morgan et al, <sup>41</sup> 1993	RCT	1B	Suicide attempters	Follow-up care: green card
Asarnow et al, <sup>42</sup> 2005	RCT	1B	Adolescents	Primary care physician education: quality improvement
Orbach and Bar-Joseph, <sup>43</sup> 1993	RCT	1B	Adolescents	Curriculum-based program
Eggert et al, <sup>44</sup> 1995	RCT	1B	Adolescents	Curriculum-based program
Thompson et al, <sup>45</sup> 2001	RCT	1B	Adolescents	Curriculum-based program
Huey et al, <sup>46</sup> 2004	RCT	1B	Psychiatric crisis in adolescents	Follow-up care
Rihmer, <sup>47</sup> 2001	Cohort study (quasi-experimental)	2B	Primary care patients in Hungary	Primary care physician education
Marusic et al, <sup>48</sup> 2004	Cohort study (quasi-experimental)	2B	Primary care patients in Slovenia	Primary care physician education
Kelly et al, <sup>49</sup> 1998	Cohort study (quasi-experimental)	2B	Primary care physicians	Primary care physician education
Oyama et al, <sup>50</sup> 2004	Cohort study (quasi-experimental)	2B	Primary care patients in Japan	Primary care physician education
Mann et al, <sup>51</sup> 2004	Cohort study (quasi-experimental)	2B	General population in Hungary	Antidepressants
Knox et al, <sup>52</sup> 2003	Cohort study (quasi-experimental)	2B	US Air Force personnel	Gatekeeper programs
Motto, <sup>53</sup> 1970	Quasi-experimental	2B	General US population	Media blackout
Loflin et al, <sup>54</sup> 1991	Cohort study (quasi-experimental)	2B	General US population	Firearm restriction
Hegerl et al, <sup>55</sup> 2003	Cohort study (quasi-experimental)	2B	General population in Germany	Public education campaign
Jorm et al, <sup>56</sup> 2005	Cohort study (quasi-experimental)	2B	General population in Australia	Public education campaign
Paykel et al, <sup>57</sup> 1998	Cohort study	2B	General UK population	Public education campaign
Akroyd and Wyllie, <sup>58</sup> 2002	Cohort study	2B	General population in New Zealand	Public education campaign
Lehfeld et al, <sup>59</sup> 2004	Cohort study	2B	General population in Germany	Public education campaign
Naismith et al, <sup>60</sup> 2001	Cohort study	2B	Primary care physicians in Australia	Primary care physician education
Hannaford et al, <sup>61</sup> 1996	Cohort study	2B	Primary care physicians in UK	Primary care physician education
Lin et al, <sup>62</sup> 2001	Cohort study	2B	Primary care physicians in US	Primary care physician education
Valentini et al, <sup>63</sup> 2004	Cohort study	2B	Primary care physicians and patients in Brazil	Primary care physician education
Pfaff et al, <sup>64</sup> 2001	Cohort study	2B	Primary care physicians in Australia	Primary care physician education
Takahashi et al, <sup>65</sup> 1998	Cohort study	2B	Primary care patients	Primary care physician education
Rutz, <sup>66</sup> 1989	Cohort study	2B	Primary care patients	Primary care physician education
Mehlum and Schweps, <sup>67</sup> 2000	Cohort study	2B	Norwegian Army	Gatekeeper education
Dieserud et al, <sup>68</sup> 2000	Cohort study	2B	General population in Norway	Chain of care
Aoun, <sup>69</sup> 1999	Cohort study	4	High-risk adults	Follow-up care
Rotheram-Borus et al, <sup>70</sup> 2000	Cohort study	4	Suicide attempters	Follow-up care

Abbreviation: RCT, randomized controlled trial.

\*Oxford Centre for Evidence Based Medicine, levels of evidence: 1A, systematic review of RCTs; 1B, individual RCT; 2A, systematic review of cohort studies; 2B, individual cohort study, low-quality RCT; 2C, ecological studies; 3A, systematic review of case-control studies; 3B, individual case-control study; 4, case series, poor-quality cohort and case-control studies.

## DATA SYNTHESIS

Heterogeneity in study methodology and populations limited formal meta-analysis, thus we present a narrative synthesis of the results for the key domains of suicide prevention interventions.

### Awareness and Education

**General Public.** Public education campaigns are aimed at improving recognition of suicide risk and help seeking through improved understanding of the causes and risk factors for suicidal behavior, particularly mental illness. Public education also seeks to reduce stigmatization of mental illness and suicide and challenges the acceptance of suicide as inevitable, as a national character trait, or as an appropriate solution to life problems, including serious medical illness. Despite their popularity as a public health intervention, the effectiveness of public awareness and education campaigns in reducing suicidal behavior has seldom been systematically evaluated.

Studies in Germany,<sup>55</sup> the United Kingdom,<sup>57</sup> Australia,<sup>56</sup> and New Zealand<sup>58</sup> suggest modest effects of public education campaigns on attitudes regarding the causes and treatment of depression. Such public education and awareness campaigns, largely about depression, have no detectable effect on primary outcomes of decreasing suicidal acts or on intermediate measures, such as more treatment seeking or increased antidepressant use.<sup>57,58,113</sup> The German study showed an 18% decrease in suicide attempts in an intervention region after 9 months of a depression awareness campaign.<sup>59</sup> However, the decline in suicide attempts occurred without a greater improvement in attitudes in the intervention region compared with the control region.<sup>55</sup>

Other specific education strategies are aimed at youth, including school and community-based programs.<sup>114,115</sup> Few such programs are evidence-based, reflect the current state of knowledge in suicide prevention, or evaluate effectiveness and safety for

preventing suicidal behavior.<sup>114</sup> A systematic review of studies published from 1980-1995 found that knowledge about suicide improved but there were both beneficial and harmful effects in terms of help-seeking, attitudes, and peer support.<sup>22</sup> A later review of studies published from 1990-2002 also found that curriculum-based programs increase knowledge and improve attitudes to mental illness and suicide but found insufficient evidence for prevention of suicidal behavior.<sup>23</sup> A subsequent controlled trial reported lower suicide attempt rates, greater knowledge, and more adaptive attitudes about depression and suicide in the intervention group compared with in the 3 months after the intervention, but no significant benefits for rates of suicide ideation or help-seeking.<sup>29</sup> In adolescents, several studies found that improving problem solving, coping with stress, and increasing resilience enhance hypothesized protective factors but effects on suicidal behavior were unevaluated.<sup>43-45</sup>

**Primary Care Physicians.** Depression and other psychiatric disorders are underrecognized and undertreated in the primary care setting.<sup>116,117</sup> Prevention is possible because most suicides have had contact with a primary care physician within a month of death.<sup>17,18</sup> Primary care physicians' lack of knowledge about or failure to screen patients for depression may contribute to nontreatment seen in most suicides. Therefore, improving physician recognition of depression and suicide risk evaluation is a component of suicide prevention.

Some studies in the United Kingdom,<sup>61</sup> Australia,<sup>60</sup> the United States,<sup>24</sup> and Northern Ireland,<sup>49</sup> showed that programs aimed at educating primary care physicians improved detection and increased treatment of depression, but that was not shown in other studies in the United States,<sup>62</sup> Brazil,<sup>63</sup> and the United Kingdom.<sup>30</sup> Nurse case management, collaborative care, or quality improvement initiatives can further improve the recognition and management of depression<sup>27</sup> and has applica-

tion where education alone may be insufficient.

A controlled trial comparing a treatment algorithm plus depression care management with treatment as usual for late-life depression in primary care in the United States demonstrated greater improvement in patient suicidal ideation and a more favorable course of illness in the intervention group compared with the treatment-as-usual group.<sup>31</sup> An adolescent depression treatment quality improvement intervention with care managers supporting primary care physicians resulted in a 50% decrease in suicide attempts in the intervention group that was not statistically different from the control group (18%) due to the low base rate.<sup>42</sup> An Australian program that trained primary care physicians to recognize and respond to psychological distress and suicidal ideation in young people increased identification of suicidal patients by 130% (determined by the Depressive Symptom Inventory–Suicidality Subscale score), without changes in treatment or management strategies.<sup>64</sup> Studies examining suicidal behavior in response to primary care physician education programs, mostly targeting depression recognition and treatment, in specific regions in Sweden,<sup>66,118</sup> Hungary,<sup>47</sup> Japan,<sup>65</sup> and Slovenia<sup>48</sup> have all reported increased prescription rate for antidepressants and often substantial declines in suicide rates and represent the most striking known example of a therapeutic intervention lowering suicide rates.

**Gatekeepers.** Suicide prevention includes a range of interventions focused on community or organizational gatekeepers whose contact with potentially vulnerable populations provides an opportunity to identify at-risk individuals and direct them to appropriate assessment and treatment.<sup>5</sup> *Gatekeepers* include clergy, first responders, pharmacists, geriatric caregivers, personnel staff, and those employed in institutional settings, such as schools, prisons, and the military. Education covered awareness of risk factors, policy changes to encourage help-seeking, availability of resources, and efforts to

SUICIDE PREVENTION STRATEGIES

reduce stigma associated with help-seeking. In addition to gatekeeper training, these programs also promoted organization-wide awareness of mental health and suicide and facilitated access to mental health services.

To date, systematic evaluation of impact on suicidal behavior has largely been limited to multilevel programs conducted in institutional settings, such as the military where programs in the Norwegian Army<sup>67</sup> and the US Air

Force<sup>52</sup> have reported success in lowering suicide rates.

**Screening**

Screening aims to identify at-risk individuals and direct them to treatment.

**Table 2.** Ecological Studies, Level of Evidence, Population, and Prevention Strategy

Source	Study Type	Level*	Population	Prevention Strategy
Etzersdorfer and Sonneck, <sup>71</sup> 1998	Ecological	2C	General population in Austria	Media blackout
Bridges and Kunselman, <sup>72</sup> 2004	Ecological	2C	General population in Canada	Firearm restrictions
Lester and Leenaars, <sup>73</sup> 1993	Ecological	2C	General population in Canada	Firearm restrictions
Snowdon and Harris, <sup>74</sup> 1992	Ecological	2C	General population in Australia	Firearm restrictions
Ludwig and Cook, <sup>75</sup> 2000	Ecological	2C	General US population	Firearm restrictions
Ohberg et al, <sup>76</sup> 1995	Ecological	2C	General population in Finland	Pesticide restriction
Bowles, <sup>77</sup> 1995	Ecological	2C	General population in Samoa	Pesticide restriction
Carrington, <sup>78</sup> 1999	Ecological	2C	General population in Canada	Firearm restriction
Kreitman, <sup>79</sup> 1976	Ecological	2C	General UK population	Domestic gas detoxification
Lester, <sup>80</sup> 1990	Ecological	2C	General population in Switzerland	Domestic gas detoxification
Gunnell et al, <sup>81</sup> 2000	Ecological	2C	General UK population	Domestic gas detoxification
Crome, <sup>82</sup> 1993	Ecological	2C	General population	Barbiturate restrictions
Nielsen and Nielsen, <sup>83</sup> 1992	Ecological	2C	General population	Barbiturate restrictions
Yamasawa et al, <sup>84</sup> 1980	Ecological	2C	General population in Japan	Barbiturate restrictions
Hawton, <sup>85</sup> 2002	Ecological	2C	General UK population	Analgesic packaging changes
McClure, <sup>86</sup> 2000	Ecological	2C	General population in England and Wales	Catalytic converters
Kelly and Bunting, <sup>87</sup> 1998	Ecological	2C	General population in England and Wales	Catalytic converters
Shelef, <sup>88</sup> 1994	Ecological	2C	General US population	Catalytic converters
Carlsten et al, <sup>89</sup> 2001	Ecological	2C	General population in Sweden	Antidepressants
Beautrais, <sup>90</sup> 2001	Ecological	2C	General population in New Zealand	Barriers to jumping
Gibbons et al, <sup>91</sup> 2004	Ecological	2C	General US population	Antidepressant use plus introduction of lower-toxicity antidepressants
Olsson et al, <sup>92</sup> 2003	Ecological	2C	US adolescents	Antidepressants
Hall et al, <sup>93</sup> 2003	Ecological	2C	General population in Australia	Antidepressants
Helgason et al, <sup>94</sup> 2004	Ecological	2C	General population in Iceland	Antidepressants
Takahashi, <sup>95</sup> 1999	Ecological	2C	General population in Japan	Antidepressants
Guaiana et al, <sup>96</sup> 2005	Ecological	2C	General population in Italy	Antidepressants
Simon et al, <sup>97</sup> 2005	Ecological	2C	General US population	Antidepressants
Valuck et al, <sup>98</sup> 2004	Ecological	2C	US adolescents	Antidepressants
Ludwig and Marcotte, <sup>99</sup> 2005	Ecological	2C	General population in 27 countries	SSRIs
Cantor and Slater, <sup>100</sup> 1995	Ecological	2C	General population in Australia	Firearm restrictions
Whitlock, <sup>101</sup> 1975	Ecological	2C	General population in Australia	Barbiturate restriction
Lester, <sup>102</sup> 1991	Ecological	2C	General population in the Netherlands	Domestic gas detoxification
Wiedenmann and Weyerer, <sup>103</sup> 1993	Ecological	2C	General population in Germany	Domestic gas detoxification
Lester, <sup>104</sup> 1990	Ecological	2C	General US population	Domestic gas detoxification
Oliver and Hetzel, <sup>105</sup> 1972	Ecological	2C	General population in Australia	Barbiturate restrictions
Retterstol, <sup>106</sup> 1989	Ecological	2C	General population in Norway	Barbiturate restrictions
Carlsten et al, <sup>107</sup> 1996	Ecological	2C	General population in Sweden	Barbiturate restrictions
Mott et al, <sup>108</sup> 2002	Ecological	2C	General US population	Catalytic converters
Kapur et al, <sup>109</sup> 1992	Ecological	2C	General US population	Introduction of lower-toxicity antidepressants
Wasserman and Varnik, <sup>110</sup> 1998	Ecological	2C	General population in former USSR	Alcohol restriction
Lester, <sup>111</sup> 1999	Ecological	2C	General population in Iceland	Alcohol restriction

Abbreviation: SSRIs, selective serotonin reuptake inhibitor.

\*For the definition of the Oxford Centre for Evidence Based Medicine, Levels of Evidence, see Table 1.

The focus may be on suicidal behavior directly or risk factors, such as depression or substance abuse. Screening instruments for depression, suicidal ideation, or suicidal acts administered to high school students,<sup>119</sup> juvenile offenders,<sup>120</sup> and youth in general<sup>121</sup> have reliability and validity in identifying individuals at increased risk for suicidal behavior and are reported to double the number of known at-risk individuals.<sup>122</sup> There is no evidence that screening youth for suicide induces suicidal thinking or behavior.<sup>123</sup> Acceptance of the need for treatment by identified at-risk youth and actual treatment implementation are understudied as potential barriers to the effectiveness of screening programs.

The US Preventive Services Task Force (USPSTF) review of studies of depression screening in adults in primary health care settings found a 10% to 47% increase in rates of detection and diagnosis of depression with the use of screening tools.<sup>24</sup> The effect on treatment was mixed, due to differences in study methodology. In contrast, a Canadian review of depression screening studies did not find routine screening in primary care to improve depression care.<sup>25</sup> Neither report commented on effects on suicidal behavior. In contrast, screening in localized geographic areas results in more treatment of depression and lower suicide rates.<sup>50,51,66</sup> The 2004 USPSTF<sup>26</sup> review of evidence on screening for suicide risk, as opposed to depression, found no published studies in English evaluating the effectiveness of screening for suicide risk in primary care.

### Treatment Interventions

**Pharmacotherapy.** Psychiatric disorders are present in at least 90% of suicides and more than 80% are untreated at time of death.<sup>124,125</sup> Depression is untreated or undertreated in general,<sup>116,126</sup> even after suicide attempt.<sup>127</sup> Thus, treating mood and other psychiatric disorders is a central component of suicide prevention.<sup>5</sup>

Antidepressant medications alleviate depression and other psychiatric dis-

orders.<sup>128</sup> However meta-analyses of RCTs have generally not detected benefit for suicide or suicide attempts in studies of antidepressants in mood and other psychiatric disorders,<sup>19,21</sup> perhaps due to the low base rate of suicidal behavior and insufficient systematic screening for suicidal behavior since reliance on spontaneous reporting underestimates rates of suicidal behavior.<sup>129</sup> Randomized controlled trials can be informative when higher-risk patients are studied and indicate an antisuicidal effect for lithium in major mood disorders<sup>34</sup> and clozapine in schizophrenia.<sup>32,33</sup> Few studies prospectively identified suicidal behavior as an outcome measure and systematically assessed it throughout the RCT.

Higher prescription rates of antidepressants correlate with decreasing suicide rates in adults or youth in Hungary,<sup>47</sup> Sweden,<sup>89</sup> Australia,<sup>93</sup> and the United States.<sup>91,92</sup> Geographic regions or demographic groups with the highest selective serotonin reuptake inhibitor prescription rates have the lowest suicide rates in the United States<sup>91</sup> and Australia.<sup>93</sup> Although Iceland,<sup>94</sup> Japan,<sup>95</sup> and Italy<sup>96</sup> do not show such correlations, potential reasons include lack of compliance; pre-existing low-suicide rate, resulting in a floor effect; and high rates of alcoholism that may elevate suicide rates or the effect may be confined to women because too few men seek and comply with treatment with antidepressants. Suicide rates in 27 countries fell most markedly in countries that had the greatest increase in selective serotonin reuptake inhibitor prescriptions.<sup>99</sup> Patient population studies report lower suicide attempt rates in adults treated with antidepressant medication<sup>97</sup> and in adolescents after 6 months of antidepressant treatment compared with less than two months of treatment.<sup>98</sup> The risk of an ecological fallacy, that is, inferring causality from group correlations, prevents attributing decreases in suicide rates solely to antidepressant use. Nevertheless, there is a striking correlation and plausible mechanism linking antidepressant use to declining rates

of untreated major depression and therefore suicide.

Concerns about higher rates of suicide-related adverse event reports in depressed children and adolescents taking selective serotonin reuptake inhibitors compared with placebo in RCTs have prompted regulatory bodies in the United States, the United Kingdom, and Europe to issue warnings urging clinicians to monitor suicide risk and adverse effects carefully when prescribing antidepressants to youth. Such concerns need to be weighed against the risk of untreated depression because suicide is the third leading cause of death in youth and more than 90% of suicides in depressed youth are untreated at the time of death.<sup>130</sup>

**Psychotherapy.** Promising results in reducing repetition of suicidal behavior and improving treatment adherence exist for cognitive therapy,<sup>35</sup> problem-solving therapy,<sup>28</sup> intensive care plus outreach,<sup>28</sup> and interpersonal psychotherapy,<sup>36</sup> compared with standard aftercare. Cognitive therapy halved the reattempt rate in suicide attempters compared with those receiving usual care.<sup>35</sup> In borderline personality disorder, dialectical behavioral therapy<sup>28</sup> and psychoanalytically oriented partial hospitalization<sup>37</sup> improved treatment adherence and reduced suicidal behavior compared with standard after care. Intermediate outcomes such as hopelessness and depressive symptoms improve with problem solving therapy, and suicidal ideation is decreased with interpersonal psychotherapy, cognitive behavior therapy, and dialectical behavioral therapy.<sup>26</sup>

**Follow-up Care After Suicide Attempts.** Many psychiatric disorders, including depression, are chronic and recurrent<sup>131</sup> and compliance with maintenance medication is often poor. Interventions for depression provided by primary care physicians are more effective when a case manager follows up with patients who miss appointments or need prescription renewals.<sup>132</sup> Many depressed patients who survive a suicide attempt will make further suicide

attempts,<sup>133</sup> particularly in the period shortly following psychiatric hospitalization<sup>134,135</sup> or during future major depressive episodes.<sup>136</sup> Thus, improved acute, continuation, and maintenance care, including psychiatric hospitalization, where necessary, of those with recurrent or chronic psychiatric disorders,<sup>137-139</sup> particularly patients who attempt suicide with mood disorders, has potential for prevention. Reduction of the number of psychiatric inpatient beds in Norway as part of a program of deinstitutionalization of psychiatric inpatients resulted in an increased suicide rate in the year after discharge with a standardized mortality ratio of 133(95% confidence interval, 90.1-190.7) in men and 208.5 (95% confidence interval, 121.5-333.9) in women.<sup>140</sup>

The Norwegian multidisciplinary chain-of-care networks provide follow-up care after hospital care to those who attempt suicide. Regions with chain-of-care programs have lower treatment dropout rates and fewer repeat attempts.<sup>68</sup> Intervention studies of those who attempt suicide to prevent future suicidal behavior have produced mixed results, including fewer suicides compared with a control group after regular mailings,<sup>38</sup> and fewer suicide attempts after issuing an emergency contact green card<sup>41</sup>) or use of a suicide intervention counselor to coordinate assessment and long-term treatment.<sup>69</sup> Other interventions for those who attempt suicide, including telephone follow-up, intensive psychosocial follow-up, and video education plus family therapy, resulted in no difference between standard aftercare and intervention groups in rate of reattempt or reemergent suicidal ideation.<sup>39,40,70</sup>

**Means Restriction**

Suicide attempts using highly lethal means, such as firearms in US men, or pesticides in rural China, India, and Sri Lanka, result in higher rates of death. Suicides by such methods have decreased after firearm control legislation,<sup>54,72-75,100</sup> restrictions on pesticides,<sup>76,77</sup> detoxification of domestic gas,<sup>79-81,101-103</sup> restrictions on the

prescription and sale of barbiturates,<sup>82-84,101,105-107</sup> changing the packaging of analgesics to blister packets,<sup>85</sup> mandatory use of catalytic converters in motor vehicles,<sup>86-88,108</sup> construction of barriers at jumping sites,<sup>90</sup> and the use of new lower toxicity antidepressants.<sup>91,109</sup>

Where the method is common, restriction of means has led to lower overall suicide rates: firearms in Canada<sup>78</sup> and Washington, DC,<sup>54</sup> barbiturate restriction in Australia,<sup>105</sup> domestic gas detoxification in Switzerland<sup>80</sup> and the United Kingdom,<sup>79</sup> and vehicle emissions in England.<sup>87</sup> Restrictions on access to alcohol have coincided with decreases in overall suicide rates in the former Union of Soviet Socialist Republics<sup>110</sup> and Iceland.<sup>111</sup>

Substitution of method may obscure a change in overall suicide rates, as has been observed for domestic gas detoxification among men in the United Kingdom,<sup>81</sup> in Germany,<sup>103</sup> and in the United States.<sup>104</sup> and for banning the pesticide parathion in Finland.<sup>76</sup> Despite unresolved questions about method substitution, these studies demonstrate the life-saving potential of restricting lethal means. Gauging the extent to which declining overall suicide rates are directly attributable to restriction in access to particular means requires consideration of long-term trends and confounding factors such as increased antidepressant use.

**Media**

The media can help or hinder suicide prevention efforts by being an avenue for public education or by exacerbating suicide risk by glamorizing suicide or promoting it as a solution to life's problems. The latter may encourage vulnerable individuals to attempt suicide or to be attracted to suicide hot spots portrayed in the media as discussed by Pirkis et al<sup>141,142</sup> and Gould.<sup>143</sup> Media blackouts on reporting suicide have coincided with decreases in suicide rates.<sup>53</sup> A 1987 campaign to decrease media coverage of subway suicides in Austria cut subway suicides by 80%.<sup>71</sup> The Internet is of increasing con-

**Table 3.** Postintervention Decrease in Total Suicide Rates

Intervention	Suicides, % Decline in Annual Rate
Education	
Public	Not available
Primary care physician	22-73 <sup>66,47,65</sup>
Gatekeeper	
US Air Force	40 <sup>62</sup>
Norwegian Army	33 <sup>67</sup>
Increasing antidepressant prescriptions*	3.2 <sup>91</sup>
Chain of care	Not available
Restricting lethal means	
Guns	1.5-9.5 <sup>78,147</sup>
Domestic gas	19-33 <sup>79,80</sup>
Barbiturates	23 <sup>105</sup>
Vehicle emissions	Not available
Analgesics	Not available
Media blackouts	Not available

\*There was a 414% increase in antidepressant prescriptions 1987-1999.

cern, particularly the effects of suicide chat rooms, the provision of instruction in methods for suicide, and the active solicitation of suicide-pact partners.

Educating journalists and establishing media guidelines for reporting suicide have had mixed results.<sup>144</sup> The American Foundation for Suicide Prevention and Annenberg Public Policy Center,<sup>145</sup> and The Centers for Disease Control and Prevention<sup>146</sup> in the United States have produced guidelines for the responsible reporting of suicide; however, no published studies have evaluated their impact.

**Conclusions and Future Directions**

National suicide prevention strategies have been proposed despite knowledge deficits about the effectiveness of some common key components. The relative impact of different strategies on national suicide rates is important for planning but difficult to estimate. TABLE 3 summarizes estimates of impact of different interventions on national suicide rates showing that the most promising interventions are physician education, means restriction, and gatekeeper education. Many universal or targeted educational interventions are multifaceted, and it is not known which components produce the desired outcome, or there may be longer-term trends in suicide rates that are not captured by the studies.

**Physician Education.** This increases the number of diagnosed and treated depressed patients with accompanying reductions in suicide although booster programs appear necessary. Videoconferencing and other teleconferencing consulting methods are possibilities where expert help is not available locally. However, the effect on suicide rates must be measured, as well as effects on intermediate outcomes, such as primary care physician-diagnosed cases of major depression and antidepressant prescription rates.

**Pharmacotherapy.** Randomized controlled trials are needed to prove that selective serotonin reuptake inhibitors decrease suicide rates. Their efficacy is established for major depression, the main risk factor for suicide. Education programs targeting primary care physicians should include instruction on use of antidepressants. The relationship between antidepressant use and emergent suicidal ideation and behavior in depressed children and adolescents needs further study. Because most depressed youth who attempt suicide are untreated, it is important not to prematurely discourage the use of effective antidepressants such as fluoxetine.

**Gatekeeper Education.** Where the roles of gatekeepers are formalized and pathways to treatment are readily available, such as in the military, educating gatekeepers helps reduce suicidal behavior. Demonstration projects for other gatekeepers with intermediate outcome measures, such as referral rates and psychiatric treatment rates, should be conducted.

**Means Restriction.** Restricting access to lethal methods decreases suicides by those methods. Priority should be given to the most commonly used methods in each country. The possibility of substitution of methods requires ongoing monitoring, as does compliance with restrictions such as firearm access.

**Screening.** Although screening programs have reported some success in identifying individuals with known risk factors for suicide, particularly among

high school and college student populations, further consideration needs to be given to determining the cost-effectiveness of screening general populations vs identified at-risk populations for reducing suicide rates, the predictive validity and reliability of specific screening instruments, and the appropriateness of standard suicide screening instruments across different cultures.

**Psychotherapy.** Psychotherapy alone or in combination with some antidepressants can be an effective treatment for depression, for suicidal ideation, for suicide attempts in borderline personality disorder, and for preventing new attempts after a suicide attempt. More needs to be known about the combinations of psychotherapeutic and pharmacologic interventions for short- and long-term outcomes for suicidal patients.

**Chain of Care.** After a suicide attempt, better structured collaboration between hospitals and teams providing follow-up care may improve compliance with treatment and decrease new attempts, but essential elements of postsuicide attempt interventions are yet to be identified.

**Media.** Strategies for influencing how the media reports suicide need to be implemented and evaluated.

Suicide prevention interventions should be multimodal, evidence-based, guided by specific testable hypotheses, and implemented among populations of sufficient size to yield generalizable and reliable results. Programs must include outcome measures. Finally, because most studies have been conducted in developed nations, many issues facing underresourced developing nations have not been addressed and require future studies specifically focused on suicide prevention.

**Author Affiliations:** New York State Psychiatric Institute, Division of Neuroscience (Drs Mann and Currier) and Division of Child psychiatry (Dr Schaffer), Department of Psychiatry, Columbia University, New York; Department of Psychiatry, Schneiders Childrens Medical Center of Israel (Dr Apter); Department of Mental Health and Substance Abuse, World Health Organization, Geneva, Switzerland (Dr Bertolote); Canterbury Suicide Project, Christchurch School

of Medicine and Health Sciences, Christchurch, New Zealand (Dr Beautrais); American Foundation for Suicide Prevention, New York, NY (Drs Haas and Hendin); Department of Psychiatry, Ludwig-Maximilians-Universität, Munich, Germany (Dr Hegerl); Department of Mental Health and Alcohol Research, National Public Health Institute, Helsinki, Finland (Dr Lonnqvist); Department of Psychiatry & Mental Health Research, St Vincents University Hospital, Dublin, Ireland (Dr Malone); Institute of Public Health of the Republic of Slovenia, Ljubjana, Slovenia (Dr Marusic); Suicide Research and Prevention Unit, University of Oslo, Oslo, Norway (Dr Mehlum); Centre for Adolescent Health, University of Melbourne, Melbourne, Australia (Dr Patton); Beijing Suicide Research and Prevention Center, Beijing, China (Dr Phillips); Division of Psychiatry, Unit for Social Psychiatry and Health Promotion, Academic University Hospital, Uppsala, Sweden (Dr Rutz); National Institute for Psychiatry and Neurology, Budapest, Hungary (Dr Rihmer); Department of Psychiatry and Psychotherapy, University of Würzburg, Würzburg, Germany (Dr Schmidtke); National Suicide Prevention Technical Resource Center, Centers for Disease Prevention and Control, Newton, Mass (Dr Silverman); Division of Behavior Sciences, National Defense Medical College Research Institute, Tokyo, Japan (Dr Takahashi); Estonian-Swedish Suicidology Institute, Center Behavior and Health Science, Tallinn, Estonia (Dr Varnik); Department of Public Health Sciences at Karolinska Institute, Swedish National Centre for Suicide Research and Prevention of Mental Ill-Health, Stockholm, Sweden (Dr Wasserman); and Hong Kong Jockey Club Center for Suicide Research and Prevention, University of Hong Kong, Hong Kong, China (Dr Yip).

**Author Contributions:** Dr Mann had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

**Study concept and design:** Mann, Apter, Beautrais, Haas, Hegerl, Lonnqvist, Malone, Mehlum, Schmidtke, Shaffer, Varnik, Wasserman, Yip, Hendin.

**Acquisition of data:** Mann, Apter, Bertolote, Hegerl, Lonnqvist, Malone, Marusic, Mehlum, Phillips, Silverman, Takahashi, Hendin.

**Analysis and interpretation of data:** Mann, Bertolote, Beautrais, Currier, Haas, Hegerl, Malone, Marusic, Mehlum, Patton, Rutz, Rihmer, Silverman, Hendin.

**Drafting of the manuscript:** Mann, Apter, Beautrais, Currier, Haas, Hegerl, Schmidtke, Shaffer.

**Critical revision of the manuscript for important intellectual content:** Mann, Apter, Bertolote, Beautrais, Haas, Hegerl, Lonnqvist, Malone, Marusic, Mehlum, Patton, Phillips, Rutz, Rihmer, Schmidtke, Shaffer, Silverman, Takahashi, Varnik, Wasserman, Yip, Hendin.

**Statistical analysis:** Mann, Marusic.

**Obtained funding:** Malone, Hendin.

**Administrative, technical, or material support:** Beautrais, Currier, Haas, Hegerl, Lonnqvist, Patton, Schmidtke, Silverman, Hendin.

**Study supervision:** Mann, Rutz, Rihmer.

**Financial Disclosures:** Dr Mann received a grant from GlaxoSmithKline to do a positron-emission tomography study of Alzheimer disease; otherwise, no financial disclosures were reported.

**Funding/Support:** Funding for the International Strategies Workshop was provided by an unrestricted educational grant from Pfizer Inc.

**Role of the Sponsor:** Pfizer had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

## REFERENCES

1. World Health Organization. *World Health Report 2003: Shaping the Future*. Geneva, Switzerland: World Health Organization; 2003. Available at: <http://www>